Evidence map›Paper›PMID 41226364›Full record

ReviewInternational journal of molecular sciences2025

Overcoming Treatment Challenges in HIV-Associated Mycobacterial Diseases: New Therapeutic Frontiers.

Omid Nikjeh, Seyedehparmis Rejali, Kayvan Sasaninia, Vishwanath Venketaraman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. DisseminatedInfection and drug resistance · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Omid NikjehCollege of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.
Seyedehparmis RejaliCollege of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.
Kayvan SasaniniaCollege of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.ORCID 0000-0003-4299-3621
Vishwanath VenketaramanCollege of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.ORCID 0000-0002-2586-1160

Funding

NHLBI NIH HHS R15 HL143545
6 · The paper itself

Abstract

For drug-susceptible TB, the WHO-endorsed first-line regimen (isoniazid, rifampicin, ethambutol, pyrazinamide) remains the global reference. Therapy must always be tailored to drug susceptibility, especially in MDR- and XDR-TB. HIV-associated mycobacterial infections-including

Indexed as

Antitubercular AgentsHIV InfectionsMycobacterium InfectionsTuberculosisCoinfectionHumansImmune Reconstitution Inflammatory SyndromeAntitubercular Agentsadherenceantiretroviral therapydrug resistanceHIVhost-directed and adjunctive therapeuticshost-directed therapiesimmune reconstitution inflammatory syndromeleprosyMycobacterium avium complextuberculosis

Identifiers

PMID41226364
PMCPMC12609301

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.